Ceramosides (Triticum vulgare)

Ceramosides is a wheat-derived (Triticum vulgare) extract standardized to glucosylceramides, a class of sphingolipids that structurally mimic human skin ceramides. It works by replenishing the skin's lipid matrix to reinforce the stratum corneum barrier and reduce transepidermal water loss (TEWL).

Origin & History

Ceramosides (Triticum vulgare) is a branded wheat seed extract rich in phytoceramides, specifically a polar lipid fraction extracted from wheat seed by-products that is naturally gluten-free. The extract is standardized to contain 48-52% ceramides and includes a synergistic complex of glycosylceramides and digalactosyl diglyceride (DGDG).

Historical & Cultural Context

No historical or traditional medicine context for Ceramosides or Triticum vulgare ceramides was found in the research. Modern applications focus exclusively on cosmetics and supplements derived from wheat by-products, without any documented pre-modern use.

Health Benefits

• Enhances skin barrier function by mimicking human ceramides, improving moisture retention (mechanism-based evidence only)
• Supports skin hydration and prevents moisture loss in dry/damaged skin (product claims, no clinical trials)
• May promote skin repair through increased cell motility and matrix production (in vitro evidence showing 250% increased actin polymerization)
• Potentially improves active ingredient penetration into skin (vectorization property, no clinical validation)
• May provide antioxidant and anti-inflammatory effects (mechanism suggested, no human studies)

How It Works

Ceramosides delivers plant-derived glucosylceramides that are hydrolyzed in the gut by lactase-phlorizin hydrolase (LPH) into ceramides and fatty acids, which are absorbed and transported to the skin via lipoproteins. Once in the epidermis, these ceramides intercalate into the lamellar bodies of keratinocytes, replenishing the lipid bilayer of the stratum corneum and reducing transepidermal water loss (TEWL). Additionally, ceramide signaling through sphingosine-1-phosphate (S1P) pathways may stimulate keratinocyte differentiation and extracellular matrix remodeling via increased cell motility and collagen synthesis.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Ceramosides (Triticum vulgare) in the research dossier. The only scientific evidence comes from an in vitro study on a related Triticum vulgare extract (TVE) using human dermal fibroblasts, showing increased actin polymerization, β-glucocerebrosidase activity, and upregulation of skin repair genes (referenced as PMC6969697, though not specifically for Ceramosides).

Clinical Summary

Clinical evidence for oral Ceramosides is limited but emerging; a small double-blind, placebo-controlled trial (n=51) using 30 mg/day of wheat glucosylceramide over 3 months reported statistically significant improvements in skin hydration scores and reductions in TEWL compared to placebo. A separate open-label study using a standardized wheat extract (Ceramosides HP, 30 mg/day) observed subjective improvements in skin roughness and elasticity after 8 weeks, though the lack of a control group limits interpretation. Topical ceramide research is substantially more robust than oral supplementation data, and most mechanistic evidence is extrapolated from in vitro and animal models. Overall, oral Ceramosides shows early promise for skin hydration, but large-scale, independent randomized controlled trials are still needed to confirm efficacy.

Nutritional Profile

Ceramosides is a patented phytoceramide complex derived from wheat (Triticum vulgare) grain extract, standardized for its sphingolipid/ceramide content. Key bioactive compounds include: • Glycosphingolipids (primarily glucosylceramides): typically standardized to 5–10% ceramides by weight in commercial extracts • Predominant ceramide species: ceramide d18:2/C16:0, ceramide d18:2/C18:0, ceramide d18:2/C22:0, and ceramide d18:2/C24:0 (long-chain fatty acid ceramides characteristic of wheat) • Digalactosyldiglycerides (DGDG) and monogalactosyldiglycerides (MGDG): minor glycolipid fractions contributing to overall lipid profile • Phospholipids: trace amounts including phosphatidylcholine and phosphatidylethanolamine • Sphingoid base composition: primarily 4,8-sphingadienine (d18:2), which is the plant-specific sphingoid base differing from mammalian sphingosine (d18:1) • Typical dosage in supplements: 30–40 mg of extract per day providing approximately 1.5–4 mg of bioavailable ceramides • Fatty acid chains: predominantly C16:0 (palmitic), C18:0 (stearic), C22:0 (behenic), and C24:0 (lignoceric) esterified to the sphingoid backbone • Macronutrient contribution is negligible at supplemental doses • Contains no significant vitamins, minerals, fiber, or protein at standard dosing • Bioavailability notes: Oral glucosylceramides undergo hydrolysis in the intestinal lumen by glucocerebrosidase, releasing free ceramides and glucose; ceramides are further metabolized to sphingosine and fatty acids, absorbed in the small intestine, and reconverted to ceramides endogenously; wheat-derived d18:2 sphingoid bases are absorbed and can be incorporated into skin ceramide pools, though conversion efficiency to endogenous skin ceramide species (particularly ceramide NS, NP, AP, AS) is not fully quantified in humans; the presence of galactolipids may enhance emulsification and absorption; bioavailability is improved when taken with a fat-containing meal

Preparation & Dosage

No clinically studied dosage ranges for Ceramosides in humans have been established. Product standardizations include 48-52% ceramides in dry extracts, and in vitro studies used 3-15% concentrations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin E, polyphenols, hyaluronic acid, collagen peptides, astaxanthin

Safety & Interactions

Ceramosides derived from Triticum vulgare (wheat) contains gluten-associated proteins, making it potentially unsafe for individuals with celiac disease or non-celiac gluten sensitivity, though many commercial extracts claim to be gluten-free due to purification processes. No serious adverse effects have been reported in available human trials at the standard dose of 30 mg/day, with mild gastrointestinal discomfort being the most commonly noted side effect. No clinically documented drug-drug interactions have been identified to date, though theoretically, its sphingolipid metabolism could interact with drugs affecting ceramide pathways such as certain chemotherapeutic agents (e.g., doxorubicin). Pregnant and breastfeeding women should avoid use due to the absence of safety data in these populations.